Clesrovimab
1654-004
Phase 3 mab completed
Quick answer
Clesrovimab for Respiratory Syncytial Virus Infection is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Respiratory Syncytial Virus Infection
- Phase
- Phase 3
- Modality
- mab
- Status
- completed